The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The NMPA approved T-DXd after neoadjuvant therapy, based on DESTINY-Breast05 data, in which the agent lowered the risk of recurrence or death vs T-DM1.
Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.
The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to PSV359 for Advanced FAP-Positive Solitary Fibrous Tumors
2
The OncFive: Top Oncology Articles for the Week of 10/4/2026
3
GI Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2026
4
Five Under 5: Top Oncology Videos for the Week of 10/5/2026
5